Objective To study the clinical features of children with rhabdomyosarcoma (RMS) and the influencing factors for prognosis. Methods A retrospective analysis was performed on the clinical and follow-up data of 20 children with RMS who were admitted to the Department of Pediatric Hematology, Xiangya Hospital of Central South University, from June 2014 to September 2020. Results The most common clinical symptoms of the 20 children with RMS at the first visit were painless mass (13/20, 65%), exophthalmos (4/20, 20%), and abdominal pain (3/20, 15%). According to the staging criteria of Intergroup Rhabdomyosarcoma Study Group (IRSG), there was 1 child (5%) with stage I RMS, 4 (20%) with stage II RMS, 9 (45%) with stage III RMS, and 6 (30%) with stage IV RMS. The median follow-up time was 19 months for the 20 children (range: 3-93 months), with a 2-year overall survival (OS) rate of 79.5% (95%CI: 20.1-24.3) and a 2-year event-free survival (EFS) rate of 72.0% (95%CI: 19.5-23.9). Pleomorphic RMS was associated with the reduced 2-year OS rate (P<0.05), and distant metastasis, IRSG stage IV RMS, and high-risk RMS were associated with the reduced 2-year EFS rate (P<0.05). Conclusions RMS has no specific clinical symptoms at the first visit, with painless mass as the most common symptom. Distant metastasis, IRSG stage, and risk degree may be associated with the prognosis of children with RMS. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(9): 1036-1041
Key words
Rhabdomyosarcoma /
Clinical feature /
Prognosis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 中华医学会病理学分会儿科病理学组, 中国抗癌协会小儿肿瘤专业委员会病理学组, 福棠儿童医学发展研究中心病理专业委员会. 儿童横纹肌肉瘤病理诊断规范化专家共识[J]. 中华病理学杂志, 2021, 50(10): 1110-1115. PMID: 34619862. DOI: 10.3760/cma. j. cn112151-20210112-00033.
2 Bánusz R, Váradi Z, Varga E, et al. Diagnosis and treatment of childhood soft tissue sarcomas[J]. Magy Onkol, 2014, 58(1): 59-64. PMID: PMID:24712008.
3 Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group[J]. J Clin Oncol, 2002, 20(11): 2672-2679. PMID: 12039929. DOI: 10.1200/JCO.2002.03.137.
4 Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies[J]. Pediatr Blood Cancer, 2012, 59(1): 5-10. PMID: 22378628. PMCID: PMC4008325. DOI: 10.1002/pbc.24118.
5 徐艳丽, 施诚仁, 谈珍, 等. 多学科综合治疗71例儿童横纹肌肉瘤的效果评估[J]. 中国肿瘤临床, 2020, 47(22): 1145-1151. DOI: 10.3969/j.issn.1000-8179.2020.22.809.
6 李艳华, 杨静薇, 廖雪莲, 等. 儿童横纹肌肉瘤分层化学治疗疗效及生存因素分析[J]. 同济大学学报(医学版), 2020, 41(3): 373-377. DOI: 10.16118/j.1008-0392.2020.03.019.
7 van Ewijk R, Schoot RA, Sparber-Sauer M, et al. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma—joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology[J]. Pediatr Radiol, 2021, 51(10): 1940-1951. PMID: 34137936. PMCID: PMC8426307. DOI: 10.1007/s00247-021-05081-0.
8 中国抗癌协会小儿肿瘤专业委员会, 中华医学会儿科学分会血液学组, 中华医学会小儿外科学分会肿瘤组. 中国儿童及青少年横纹肌肉瘤诊疗建议(CCCG-RMS-2016)[J]. 中华儿科杂志, 2017, 55(10): 724-728. PMID: 29050107. DOI: 10.3760/cma.j.issn.0578-1310.2017.10.002.
9 倪燕, 赵强, 闫杰, 等. 儿童横纹肌肉瘤复发及预后的影响因素分析[J]. 中国肿瘤临床, 2018, 45(18): 950-954. DOI: 10.3969/j.issn.1000-8179.2018.18.772.
10 文圆, 张伟令, 张谊, 等. 儿童头颈部横纹肌肉瘤疾病进展的危险因素及预后分析[J]. 中华实用儿科临床杂志, 2021, 36(15): 1152-1156. DOI: 10.3760/cma.j.cn101070-20210128-00124.
11 赵敏, 冯晨, 王建文, 等. 儿童横纹肌肉瘤23例临床分析[J]. 中国当代儿科杂志, 2011, 13(8): 657-660. PMID: 21849118.
12 Morris CD, Tunn PU, Rodeberg DA, et al. Surgical management of extremity rhabdomyosarcoma: a consensus opinion from the Children's Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe[J]. Pediatr Blood Cancer, 2020: e28608. PMID: 32776456. DOI: 10.1002/pbc.28608.
13 Rogers TN, Seitz G, Fuchs J, et al. Surgical management of paratesticular rhabdomyosarcoma: a consensus opinion from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe[J]. Pediatr Blood Cancer, 2021, 68(4): e28938. PMID: 33522706. PMCID: PMC9019908. DOI: 10.1002/pbc.28938.
14 段超, 张伟令, 孙青, 等. 儿童及青少年横纹肌肉瘤多中心临床研究——CCCG-RMS-2016方案近期疗效研究报告[J]. 中国小儿血液与肿瘤杂志, 2020, 25(5): 253-257. DOI: 10.3969/j.issn.1673-5323.2020.05.002.
15 Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial[J]. Lancet Oncol, 2005, 6(9): 649-658. PMID: 16129365. DOI: 10.1016/S1470-2045(05)70291-6.
16 Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial[J]. Pediatr Blood Cancer, 2008, 50(4): 739-745. PMID: 18286501. DOI: 10.1002/pbc.21494.
17 Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2019, 20(11): 1566-1575. PMID: 31562043. DOI: 10.1016/S1470-2045(19)30617-5.
18 Subbiah V, Meyer C, Zinner R, et al. Phase Ib/II study of the safety and efficacy of combination therapy with multikinase VEGF inhibitor pazopanib and MEK inhibitor trametinib in advanced soft tissue sarcoma[J]. Clin Cancer Res, 2017, 23(15): 4027-4034. PMID: 28377484. PMCID: PMC5754188. DOI: 10.1158/1078-0432.CCR-17-0272.
19 Mascarenhas L, Chi YY, Hingorani P, et al. Randomized phase II trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: a report from the Children's Oncology Group[J]. J Clin Oncol, 2019, 37(31): 2866-2874. PMID: 31513481. PMCID: PMC6823886. DOI: 10.1200/JCO.19.00576.
20 Wen Y, Huang D, Zhang W, et al. Radiation therapy is an important factor to improve survival in pediatric patients with head and neck rhabdomyosarcoma by enhancing local control: a historical cohort study from a single center[J]. BMC Pediatr, 2020, 20(1): 265. PMID: 32471472. PMCID: PMC7260775. DOI: 10.1186/s12887-020-02165-y.
21 Cameron AL, Elze MC, Casanova M, et al. The impact of radiation therapy in children and adolescents with metastatic rhabdomyosarcoma[J]. Int J Radiat Oncol Biol Phys, 2021, 111(4): 968-978. PMID: 34217789. DOI: 10.1016/j.ijrobp.2021.06.031.
22 Milewski D, Shukla S, Gryder BE, et al. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma[J]. Oncogene, 2021, 40(12): 2182-2199. PMID: 33627785. PMCID: PMC8005492. DOI: 10.1038/s41388-021-01694-9.
PDF(582 KB)
